Filing Details

Accession Number:
0000899243-20-003247
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-02-05 16:05:28
Reporting Period:
2020-02-03
Accepted Time:
2020-02-05 16:05:28
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1731831 Eidos Therapeutics Inc. EIDX Pharmaceutical Preparations (2834) 463733671
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1758363 Cameron Turtle C/O Eidos Therapeutics, Inc.
101 Montgomery Street, Suite 2000
San Francisco CA 94104
Chief Business Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-02-03 5,000 $13.20 90,155 No 4 M Direct
Common Stock Acquisiton 2020-02-03 2,500 $17.00 92,655 No 4 M Direct
Common Stock Disposition 2020-02-03 5,289 $53.32 87,366 No 4 S Direct
Common Stock Disposition 2020-02-03 7,211 $53.89 80,155 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2020-02-03 5,000 $0.00 5,000 $13.20
Common Stock Stock Option (Right to Buy) Disposition 2020-02-03 2,500 $0.00 2,500 $17.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
90,000 2028-11-05 No 4 M Direct
21,420 2028-06-20 No 4 M Direct
Footnotes
  1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
  2. Represents the weighted average sale price of the shares sold from $52.56 to $53.55 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported in footnotes 2 and 3.
  3. Represents the weighted average sale price of the shares sold from $53.60 to $54.30 per share.
  4. 25% of the shares subject to this option vested and became exercisable on November 5, 2019 and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.
  5. The shares subject to this option vest and become exercisable in 48 equal monthly installments following June 18, 2018, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.